Johnson & Johnson Consumer Health Reveals New Skin Health Research at American Academy of Dermatology VMX 2021
SKILLMAN, N.J., April 23, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Health will present new research including among the first of its kind study on restorative skincare for cancer patients, new advances in multicultural skincare, the emotional impact of acne, and more to the world's leading dermatologists at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) April 23-25, 2021. A total of 16 posters will be presented at this year's conference, including three oral presentations.
"At Johnson & Johnson Consumer Health, we pride ourselves on developing innovative solutions through next-generation science for healthier skin," said Caroline Tillett, Global Head R&D, Johnson & Johnson Consumer Health. "Over the past year, we made substantial advancements in critical research programs that will support major consumer health needs. Our new research with cancer patients, acne sufferers, and diverse communities demonstrates our unwavering commitment to provide skincare options across the spectrum of skin types, tones, and needs."
Johnson & Johnson Consumer Health will be presenting three oral presentations at the AAD VMX 2021:
"Cancer patients undergoing treatment frequently report negative skin-related side effects such as xerosis and pruritus, or dry skin and itch, yet there are few studies evaluating potential remedies," said Dr. Georgios Stamatas, Research Associate Director and Fellow, Johnson & Johnson Consumer Health. "Our deep knowledge of the therapeutic benefits of oat led us to believe an Avena Sativa (Oat) daily skincare regimen can help replenish the skin barrier in cancer patients who experience xerosis and pruritus due to systemic oncological treatment. We are excited to share the results of this study at AAD in the coming days."
"Sun protection, including sunscreen, is vital for everyone to protect their skin from sun damage and help prevent skin cancer. However, a common misconception is that Black and Brown communities do not benefit from sunscreen," said Barbara Green, Senior Director, Skin Health Translational Science, Johnson & Johnson Consumer Health. "We formulated products specifically to be invisible on the skin while feeling weightless and breathable. We are looking forward to presenting results of a one-week consumer experience study of 160 consumers representing all Fitzpatrick skin types and ethnicities equally."
Through its rigorous scientific process, Johnson & Johnson Consumer Health brings leading skincare products to consumers and healthcare professionals worldwide. Its recent skincare innovations include: Neutrogena's patented Rapid Firming Peptide Contour Lift Cream, which features a proprietary matrix-building dipeptide that reduces the look of fine lines and specifically targets five anti-sagging markers in the skin; Aveeno's Restorative Skin Therapy line, a three-step regimen clinically proven effective on xerosis and pruritus in adult oncology patients; and new Neutrogena Invisible Daily Defense sunscreens reported to be "invisible on all skin tones."
Johnson & Johnson Consumer Health poster presentations at the meeting include:
About the Consumer Health business of Johnson & Johnson
At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee's®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson's®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.
SOURCE Johnson & Johnson